Novartis, Paratek in deal to develop MRSA drug

10/8/2009 | Reuters

Novartis acquired exclusive global rights to PTK 0796, Paratek Pharmaceuticals' treatment for methicillin-resistant Staphylococcus aureus and other drug-resistant bacteria. The drug is in Phase III trials and has shown promise in safety and tolerability.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY